Vincerx Pharma, Inc. Common Stock
VINC
VINC was delisted on the 22nd of April, 2025.
12 hedge funds and large institutions have $19.8M invested in Vincerx Pharma, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 7 closing their positions.
146% more capital invested
Capital invested by funds: $8.05M → $19.8M (+$11.7M)
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
33% more funds holding
Funds holding: 9 → 12 (+3)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$6.41M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.46M |
| 3 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$1.27M |
| 4 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
+$1.02M |
| 5 |
JGC
J. Goldman & Co
New York
|
+$878K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.99M |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$1.59M |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$605K |
| 4 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
-$443K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$398K |
VINC Hedge Fund Activity: Q3 2020 in Review
12 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q3 2020, worth a combined $19.8M — up 146% from $8.05M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new VINC positions and 7 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $6.41M. The largest seller was Monashee Investment Management, exiting entirely with an estimated $1.99M sold.
- 12 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q3 2020, up from 9 in Q2 2020.
- Funds reported $19.8M of Vincerx Pharma, Inc. Common Stock stock for Q3 2020, up 146% quarter-over-quarter.
- 10 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q3 2020 and 7 closed out, a net change of +3 holders.
- The largest Vincerx Pharma, Inc. Common Stock buyer in Q3 2020 was EcoR1 Capital, an estimated $6.41M added.
- The largest Vincerx Pharma, Inc. Common Stock seller in Q3 2020 was Monashee Investment Management, an estimated $1.99M sold.
Based on aggregated 13F filings for Q3 2020.